A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT02718833 Phase 2 ACTIVE_NOT_RECRUITING

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

Details

Lead sponsor	Massachusetts General Hospital
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	52
Start date	2016-06-21
Completion	2027-12

Conditions

• Multiple Myeloma

Interventions

• Elotuzumab
• Pomalidomide
• Bortezomib
• Dexamethasone

Primary outcomes

• Overall response rate by International Myeloma Working Group criteria. — 2 years
  To evaluate the objective response rate (partial response or better) of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in patients with relapsed and refractory multiple myeloma and who have received at least two prior therapies and are relapsed and/or refractory to both lenalidomide and bortezomib.
• Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 — 2 years

Countries

United States